Alnylam Pharma (ALNY): New Phase I/II Study for Chronic Hep B - FBR

FBR Capital analyst, Christopher James, noted that Alnylam Pharma (NASDAQ: ALNY) announced the initiation of its Phase I/II study with ALN-HBV for potential treatment of patients with chronic hepatitis B virus (HBV) infection. The analyst has held a keen interest in the ALN-HBV program, which was highlighted at FBR's Infectious Disease Conference but seems widely underappreciated by the Street.

In November 2015, ALNY presented positive preclinical evidence with ALN-HBV demonstrating potent and durable reductions in HBV surface antigen (HBsAg). ALNY holds an untarnished track record regarding reproducing its preclinical results in human subjects. Initial clinical data is expected in mid 2017.

ALN-HBV is a novel subcutaneous (SC) investigational RNAi therapeutic with potential to inhibit all steps of the HBV life cycle and treat patients with both HBeAg-positive and HBeAg-negative disease.

No change to Outperform rating or price target of $180.

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $61.52 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• TechnipFMC (FTI) PT Raised to $30 at BTIG
• Bristol-Myers Squibb Co. (BMY) PT Lowered to $64 at Truist Securities